<DOC>
	<DOC>NCT02569502</DOC>
	<brief_summary>This study will evaluate the safety and tolerability of subcutaneous Fuzeon in patients with advanced HIV-1 infection unable to construct an appropriate treatment regimen from currently available antiretroviral agents. The anticipated time on study treatment is 3-12 months, and the target sample size is 9 individuals.</brief_summary>
	<brief_title>A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>Adult or adolescent patients greater than (&gt;)16 years of age HIV1 infection CD4 count less than (&lt;)350/cubic millimeters (mm^3) HIV RNA viral load &gt;10,000 copies per milliliter (copies/mL) while on highly active antiretroviral therapy (HAART) Documented resistance, treatmentlimiting toxicity, and/or &gt;=6 months' prior experience with each of 3 currently available classes of antiretroviral drugs. Women who are pregnant or breastfeeding; Patients unable to selfinject; Active, untreated opportunistic infection.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>